Ceritinib (LDK378) prevents bone loss via suppressing Akt and NF-κB-induced osteoclast formation

Overview of attention for article published in Frontiers in endocrinology, November 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (72nd percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 2 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 10,650 followers.

Ceritinib (LDK378) prevents bone loss via suppressing Akt and NF-κB-induced osteoclast formation #lymphoma #lymsm https://t.co/stQGATAZXF

25 Nov 2022

Reply Repost Favourite

Ceritinib (LDK378) –used in patients with non-small cell lung cancer- prevents bone loss via suppressing Akt and NF-κB-induced osteoclast formation in vitro and in OVX mouse model. Wenxin He et al. Front Endocrinol 8 Nov 2022 https://t.co/9MsZS88V1F …inhib

15 Nov 2022

Reply Repost Favourite

New Research: Ceritinib (LDK378) prevents bone loss via suppressing Akt and NF-κB-induced osteoclast formation: Background Ceritinib is used for the treatment of patients with anaplastic lymphoma kinase (ALK)-rearranged non-small… https://t.co/hVZnNmFZZF

08 Nov 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.